| Hazard Information | Back Directory | [Uses]
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers[1]. | [in vivo]
Naxitamab (Hu3F8; 100 mg/kg; i.v.; twice a week, for 4 weeks; athymic nude mice with LAN-1 xenografts) inhibits tumor growth in neuroblastoma xenografts[1]. | Animal Model: | Female athymic nude mice with LAN-1 xenografts[1] | | Dosage: | 100 mg/kg | | Administration: | Intravenous injection; twice a week, for 4 weeks | | Result: | Inhibited tumor growth and prolonged the survival time. |
| [References]
[1] Cheung NK, et, al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012 Jul 1;1(4):477-486. DOI:10.4161/onci.19864
[2] Markham A. Naxitamab: First Approval. Drugs. 2021 Feb;81(2):291-296. DOI:10.1007/s40265-021-01467-4 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|